Table 2. . Replications identified from phenome-wide association study in European–Americans and corresponding results in African–Americans.
| PheCode | SNP | Gene | Coded allele | Controls, n | Cases, n | Control, CAF | Case, CAF | OR (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|---|
|
(A) European–Americans | |||||||||
| Gout |
rs2231142 |
ABCG2 |
A |
5528 |
363 |
0.11 |
0.17 |
1.73 (1.41–2.12) |
1.73 × 10-7 |
| Jaundice |
rs4149056 |
SLCO1B1 |
C |
5058 |
154 |
0.15 |
0.25 |
1.67 (1.33–2.11) |
2.35 × 10-4 |
| Tobacco use disorder |
rs28399433 |
CYP2A6 |
G |
4882 |
1132 |
0.03 |
0.04 |
0.81 (0.66–0.90) |
0.04 |
| Atrophic gastritis |
rs4244285 |
CYP2C19 |
A |
3366 |
77 |
0.15 |
0.25 |
1.95 (1.43–2.65) |
3.45 × 10-4 |
| Chemotherapy |
rs4986782 |
NAT1 |
A |
4664 |
956 |
0.02 |
0.03 |
1.85 (1.37–2.50) |
6.45 × 10-5 |
|
(B) African–Americans | |||||||||
| Gout |
rs2231142 |
ABCG2 |
A |
617 |
64 |
0.03 |
0.03 |
1.20 (0.48–2.97) |
0.74 |
| Jaundice |
rs4149056 |
SLCO1B1 |
C |
579 |
22 |
0.03 |
0.02 |
0.71 (0.12–3.97) |
0.75 |
| Tobacco use disorder |
rs28399433 |
CYP2A6 |
G |
525 |
163 |
0.10 |
0.07 |
0.67 (0.41–1.12) |
0.13 |
| Atrophic gastritis |
rs4244285 |
CYP2C19 |
A |
381 |
3 |
0.17 |
0.00 |
0.00 (0.00–∞) |
0.99 |
| Chemotherapy | rs4986782 | NAT1 | A | 594 | 75 | 0.003 | 0.00 | 0.00 (0.00–∞) | 0.98 |
CAF: Coded allele frequency; OR: Odds ratio.